Eli Radiopharma Raises Nearly RMB 400 Million in Series A Funding
Hangzhou-based Eli Radiopharma announced on November 12, 2026, that it had completed a Series A financing of nearly RMB 400 million. The proceeds will primarily support advancement of the company’s core radiopharmaceutical pipeline toward clinical development. Huagai Capital led the round, with Bayland Capital as co-lead. Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management and Grand Flight Investment also participated. Existing…